, functioning, and depressive symptom severity are important in assessing the burden of illness of major depressive disorder (MDD) 
Introduction

Ma jor depressive disorder (MDD) is one of
Similarly, poor QoL, functional impairment and more severe symptoms could also result in worsening of depression. 11 This bidirectional relationship continues to interfere with the precision of outcome measurements. Although widely used, clinician-rated measures of symptom severity are not immune from patient bias since they are primarily based on patient reports in addition to clinician observation, and they were even reported to yield a significant discrepancy when administered to patients vs their informants. 12 Except in dysthymic and nonendogenous depressed groups, empirically designed selfreport scales tend to have a moderately high correlation with clinician-rated ones. 13 Moreover, PROs continue to provide valuable information that could not be obtained using clinician-rated measures despite the risk of minimization or magnification of the actual burden of illness. In fact, QoL by conceptual and operational definitions has to be measured by subjective reporting. Based on the WHO definitions, QoL reflects the patient's satisfaction with health and life activities, ie, work, love, and play activities by self-report, 14 whereas functioning refers to an individual's actual involvement and participation in the aforementioned activities as rated by self or observers. 15 Unless clinicians are using collateral information, functioning is primarily measured by self-rating. Individuals with MDD frequently suffer from QoL and functioning impairments, 16 and several investigators have demonstrated that treatment of severe mental disorders, including MDD, should not only focus on reduction of symptoms, but also seek to enhance levels of functioning, and more significantly improve the patient's subjective wellbeing and QoL. 17, 18 Since patients remain at the center of suffering from depression, their perceptions of the dimensions of their burden of illness using PROs should remain as fundamental tools for assessment of the effectiveness of treatment interventions, especially in the era of patient-centered health care. Descriptions of the most commonly used PROs in MDD appear in Table I . [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In order to present a real-world application of PROs, we are seeking to provide a detailed analysis of PROs before and after treatment of MDD using different interventions following the failure of first-line treatment with a selective serotonin reuptake inhibitor (SSRI). In earlier studies, we examined the effect of level 1 treatment on functioning, QoL, and the individual burden of illness for depression (IBI-D), a vector derived from a principal component analysis that captures the vast majority of the variance in PROs of depressive symptom severity, functioning, and QoL in depressed patients. 34 The present analysis aims at examining PROs in patients who failed first-line treatment with the SSRI citalopram, before and after enrolment in level 2 using seven interventions as second-line interventions in MDD. Although many publications [35] [36] [37] [38] have reported findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, patient-reported functional outcomes were seldom described. Moreover, previous publications have traditionally focused on results based on P values, whereas the current analysis adds the examination of effect sizes in order to assess more clinically meaningful effects of the interventions as assessed using patient-reported measures.
Methods
Study population
STAR*D is the largest study ever conducted on MDD treatment, and featured multiple levels of pharmacotherapy and psychotherapy trials. Patients failing one trial of SSRI monotherapy (level 1), were either switched from citalopram to sertraline, venlafaxine, bupropion, or cognitive therapy, or kept on citalopram and augmented with bupropion, buspirone, or cognitive therapy (level 2). The STAR*D study was funded by the National Institute of Mental Health (NIMH) and is the largest study aimed at analyzing subsequent treatment steps for patients with treatment-resistant MDD. The design and rationale of STAR*D are detailed elsewhere. 39 , 40 The study enrolled 4041 18-to 75-year-old outpatients with nonpsychotic 
Outcome measures
Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)
The Q-LES-Q-SF, 19 used to assess QoL, is a self-report questionnaire that measures satisfaction and enjoyment in a series of discrete domains and life activities. This study uses the short version, which has 16 items: physical health, mood, work, household activities, social relationships, family relationships, leisure time activities, ability to function in daily life, sexual drive/interest/ performance, economic status, living/housing situation, ability to get around physically, vision, and overall sense of wellbeing. Each item is scored on a 5-point Likert scale, where 1=very poor, 2=poor, 3=fair, 4=good, and 5=very good. Adding the results of the 14 first items, then dividing by the maximum score, and multiplying this figure by 100 gives a total score ranging from 0 to 100, with 0 being the lowest QoL score and 100 the highest. Community norm samples have a mean Q-LES-Q-SF score of 78.3 (standard deviation [SD], 11.3) and scores within 10% of this value, ie, Q-LES-Q-SF ≥70.47, are considered "normal", whereas Q-LES-Q-SF scores greater than 2 SD below the community norm scores, ie, Q-LES-Q-SF ≤55.7, are considered "severely impaired." 19 The Q-LES-Q-SF has a Cronbach α of 0.90 and test-retest reliability of 0.74, demonstrating strong psychometric properties. 19 
Work and Social Adjust Scale (WSAS)
The WSAS 41 was used to assess functioning. The WSAS is a five-item self-report questionnaire that measures impairment of functioning in various settings: work; home management, eg, cleaning, tidying, shopping, cooking, looking after home or children, and paying bills; social leisure time, ie, activities done with other people, such as parties, clubs, outings, dating, and home entertainment; private leisure time, ie, activities done alone, such as reading, gardening, collecting, sewing, and walking alone; and ability to form and maintain close relationships with others. Each item is scored on a visual analogue scale ranging from 0 (no impairment at all), to 8 (very severe impairment). The sum of the results of the five items gives a total score ranging from 0 (best functioning) to 40 (worst functioning). Severe impairment is indicated by scores above 20. 41 The WSAS has a Cronbach α varying from 0.70 to 0.94 and test-retest reliability of 0.73, also demonstrating strong psychometric properties. Table I . Continued
C l i n i c a l r e s e a r c h Quick Inventory of Depressive SymptomatologySelf Report (QIDS-SR)
The QIDS-SR 28 was used to assess severity of depressive symptoms. The QIDS-SR is a 16-item questionnaire corresponding to the nine DSM-IV criteria of major depression: one item for each of the following symptoms: depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/ decision making, and suicidal ideation; four items to assess sleep: early, middle, and late insomnia, and hypersomnia; two items to assess psychomotor disturbance: agitation and retardation; and four items to assess appetite/weight: appetite increase or decrease, and weight increase or decrease. Each item is rated 0 to 3. The QIDS-SR score is calculated by summing the scores of the items. In domains utilizing more than one item (eg, the four items for sleep disturbance), only the highest score is utilized in the total score. 28 The QIDS-SR scores range from 0 (not depressed) to 27 (most severely depressed). A score of five or less indicates remission, which is the goal of treatment. 28 The QIDS-SR has high internal consistency (Cronbach α, 0.86) and is highly associated with the three versions of the clinician-rated Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, and the Beck Depression Inventory. 28 
Individual Burden of Illness for Depression (IBI-D)
The burden of illness was measured using the IBI-D, a newly introduced measure that incorporates QoL, functioning, and depressive symptom severity. 34 The IBI-D is the first and only statistically significant principal component obtained from a principal component analysis of the above three well-validated PROs of depressive symptom severity (QIDS-SR), functioning (WSAS), and QoL (Q-LES-Q-SF). IBI-D is a z-score that references patients in level 1 of STAR*D, where values around 0 represent a burden similar to the average depressed patient, a burden greater than +2 indicates that the patient has an unusually high burden (higher than the top 2% of depressed patients), and values lower than -2 indicate that the patient has a lower burden (lower than 98% of depressed patients). The IBI-D was shown to adequately capture the multidimensional impact of antidepressant treatment, 42 and to adequately predict relapse in MDD. 43 
Statistical methods
Summary values are expressed as means and SDs for continuous variables, and frequencies (%) for categorical variables. We calculated effect sizes using Cohen's standardized differences (Cohen's d) , in order to assess clinical significance in addition to statistical significance. Cohen's d values of 0.2, 0.5, and 0.8 describe small, medium, and large effects, respectively. Within the treatment groups, changes from entry to exit (∆s) on continuous variables were assessed for significance using paired t tests. Between-group differences on continuous variables were assessed for significance using independent sample t tests. We calculated and compared the proportions of patients with normal QoL (using Q-LES-Q-SF) and functioning (using WSAS) and with severe impairments on both measures. Within the treatment groups, preintervention vs postintervention P values were calculated using McNemar's test for related proportions. Five tests were performed for each outcome measure: two within-group tests and three between-group tests (entry, change, and exit). Thus, we used a Bonferroniadjusted 0.01 significance level for each test. Analyses were performed using SAS software version 9.2 (SAS Institute Inc, Cary, NC, USA).
Results
STAR*D used an equipoise stratified randomized design. 44 In level 2, patients with the help of their clinicians considered either switching or augmenting citalopram using a new medication or cognitive therapy. Patients could decline any strategy, however there had to be at least two possible strategies, to one of which the patient was randomized. 45 
Study population demographics
Complete QoL, functioning, and depressive symptom severity data from STAR*D level 2 trial subjects were analyzed (n=749). The mean age was 44.4 years (SD, 12.4) with a range from 18.8 to 75 years. Caucasians represented 81.6% (n=611), while Hispanics accounted for 12.3% (n=92) in this sample. Females made up 60.1% (n=450) and 25.1% (n=188) were college graduates. Slightly more than half, 51.9% (n=389), were employed at the start of the study and 42.1% (n=330) were living with a spouse or partner. 
Pretreatment scores
The Q-LES-Q-SF scores ranged from 38.5 to 45.2 with a mean score of 42.1 (SD, 15.5). The WSAS scores ranged from 22.4 to 24.1 with a mean score of 23.6 (SD, 9.0). The QIDS-SR scores ranged from 13.1 to 15.7 with a mean score of 14.3 (SD, 4.7). No statistically significant differences were found between the seven treatment groups. It is especially important to note the high effect sizes for venlafaxine and cognitive therapy (Cohen's d, >0.8), indicating large, clinically significant improvements. In general, the effect sizes were higher for patient-reported depressive symptom severity, than for QoL or functioning.
Post-treatment scores: impact of treatment on QoL, functioning, and depressive symptoms
Proportions of patients scoring within normal QoL and functioning
Level 2 STAR*D entry and exit proportions of patients with normal QoL (Q-LES-Q-SF ≥78.3) and functioning are presented in Table II . 19, 46, 47 
Pretreatment proportions
Before treatment, depressed patients scoring for a normal QoL ranged from 0% to 5%, with a mean proportion of 2.9%. Patients within normal functioning ranged from 1.7% to 11.5%, with a mean proportion of 6.4%.
Post-treatment proportions: impact of treatment
The posttreatment data revealed a statistically significant increase in the proportion of patients with normal QoL and functioning. All P values were less than 0.0005 for QoL and functioning, except for citalopram plus cognitive therapy (QoL, P=0.63; functioning, P=0.012). However, the proportion of patients with normal QoL and functioning upon exit ranged from Q-LES-Q-SF scores of 6.4% to 31.3%, and WSAS scores of 21.3% to 43.8%, with the mean percentage of patients with normal QoL of 19.5%, and with normal functioning of 31.9%. In other words, following treatment, only 1 out of 5 patients achieved a normal QoL and less than one third of patients achieved normal functioning.
Proportions of patients with severe impairments in QoL and functioning
Level 2 STAR*D entry and exit proportions of patients with severe impairments in QoL (2 SD below community norms, ie, Q-LES-Q-SF <55.7) and functioning (WSAS >20) are displayed in Table II .
19,46,47
Pretreatment proportions
Before treatment, severe impairments in QoL and functioning were detected in a large proportion of patients, with an overall higher percentage of patients with severely impaired QoL (range, 77.2% to 93.6%; mean, 83.3%) than functioning (range, 57.7% to 66.1%; mean, 62.5%), ie, nearly 4 out of 5 patients suffer from severe QoL impairment and 2 out of 3 patients suffer from severe functional impairment.
Post-treatment proportions: impact of treatment
The post-treatment data revealed a statistically significant reduction in the proportion of patients suffering from severely impaired QoL (P<0.005). Several of the functional impairment results were not statistically significant at the Bonferroni-adjusted 0.01 significance level. The proportion of patients severely impaired in QoL and functioning upon exit ranged from 68.6% to 43.8% (mean, 59.5%) and from 49.6% to 37.5% (mean, 44.3%), respectively, with a mean of 59.5% (QoL) and of 44.3% (functioning) for the whole sample. In other words, nearly 2 out of 3 patients still struggled with severe impairments in QoL, and less than half still experienced severe impairments in functioning. Nonremitters had substantially smaller proportions of patients within normal QoL and functioning, and larger proportions with severe impairments in QoL and functioning at exit.
Individual burden of illness for depression (IBI-D) scores
Level 2 STAR*D entry and exit scores for burden of illness for depression (IBI-D) are displayed in Table III .
Pretreatment scores
Generally, the baseline IBI-D scores of remitters were lower than that of nonremitters, suggesting that remitters started out with less burden of illness overall. For remitters (P<0.0001), the treatment group with the most burden at baseline was cognitive therapy (z score, -0.13), Table II . Proportions of patients with normal quality of life (QoL) and functioning before and after each intervention. Normal QoL is defined as Q-LES-Q-SF scores within 10% of community norms, and severe impairment is defined as Q-LES-Q-SF scores greater than 2 standard deviations (SD) below the community norms. Since community norm samples have an average Q-LES-Q-SF of 78.3 (SD, 11.3), a Q-LES-Q-SF ≥70.47 is considered within normal and a Q-LES-Q-SF ≤55.7 is considered severely impaired. 19, 46, 47 Normal functioning is defined as WSAS scores of less than 10 and severe impairment is defined as WSAS scores of more than 20. 25 n, number while the treatment group with the least burden was citalopram plus bupropion (z score, -0.77) followed by citalopram plus buspirone (z score, -0.76). For nonremitters (all P values, <0.0001), the treatment group with the most burden was sertraline (z score, 0.25) followed by venlafaxine (z score, 0.24), while the treatment group with the least was citalopram plus cognitive therapy (z score, -0.10) followed by cognitive therapy (z score, -0.11) and citalopram plus bupropion (z score, -0.11).
Post-treatment scores: impact of treatment
Posttreatment, the data revealed an overall statistically significant reduction in the burden of illness for depression (all P values, <0.0001). For both remitters and nonremitters (all P values, <0.0001), the treatment group with the least burden upon exit was cognitive therapy (change for IBI-D scores in remitters from -0.13 to -2.68; nonremitters from -0.11 to -0.50). Additionally, the treatments that led to the greatest decrease in burden (all P values, <0.0001) were cognitive therapy (change for IBI-D scores in remitters, -2.55; nonremitters, -0.39), sertraline (change for IBI-D scores in remitters, -1.96; nonremitters, -0.42), and venlafaxine (change for IBI-D scores in remitters, -1.90; nonremitters, -0.49).
Differences between the seven interventions on PROs
There were no statistically significant differences between the interventions. Interestingly, switching to cognitive therapy stood out numerically with the greatest effect size for QoL (Cohen's d, 0.73), the largest proportion of patients with normal QoL and functioning upon exit (31.3%), the lowest proportion of patients severely impaired (43.8%), as well as the lowest IBI-D score upon exit (z score, -0.50).
Discussion
The main findings of the present study are: (i) PROs show that the seven level 2 treatment options produced significant functional improvements that were significant both statistically (P<0.01) and clinically (Cohen's d>0.4); and (ii) patient-reported functional outcomes revealed that a substantial proportion of patients who had failed a first-line trial with citalopram, still experienced grave impairments in QoL and functioning after treatment with second-line augmentation or switching interventions, an effect that is more pronounced in nonremitters.
The seven different treatments of MDD in patients who have failed initial citalopram monotherapy show a significant positive impact on QoL, functioning, and depressive symptom severity using patient-reported measures. The use of effect size enabled us to assess the magnitude of this impact after ascertaining that it did not happen by chance, ie, after establishing statistical significance. On depressive symptom severity, other STAR*D analyses 36, 38 concluded that bupropion, sertraline, venlafaxine, and cognitive therapy, as well as citalopram plus bupropion, citalopram plus buspirone, and citalopram plus cognitive therapy, lead to similar outcomes. However, this study is unique in including patient-reported functional outcomes. In general, the effect sizes were the highest for patient-reported depressive symptom severity, followed by functioning, then QoL. Switching to cognitive therapy alone, after failing first-line SSRI treatment, achieved numerical superiority, which is a finding that might be worthy of future exploration. Although the usefulness of cognitive therapy in refractive MDD has long been established 48 with respect to reducing symptoms, the present study showed that the cognitive therapy group displayed the largest proportion of patients with normal QoL and functioning upon exit, the smallest proportion of patients severely impaired, the greatest effect size for both QoL and functioning, and also displayed the lowest IBI-D score upon exit. Previous STAR*D analyses utilized remission (not patient-reported QoL or functioning) as primary outcomes to show that cognitive therapy alone, or in addition to citalopram, was as effective as the other level 2 pharmacologic options with "comparable outcomes." 36 The above results for cognitive therapy need to be interpreted with extreme caution; the results should only be considered as hypothesis-generating, since STAR*D was not designed to compare it with other treatments and the sample size was small.
Although the impact of the seven interventions is statistically and clinically significant, a substantial proportion of patients failed to achieve normal scores on QoL and functional patient-reported measures. Nonremitters showed remarkably large proportions with severe impairments in QoL and functioning. We also observed considerably small proportions of nonremitters who experienced normal QoL and functioning. Moreover, our analysis shows that, even after achieving remission, only half of the remitters scored a normal QoL. This finding adds more credence to the notion that remission (mini-C l i n i c a l r e s e a r c h mal or no symptoms) does not reflect full recovery of functional outcomes, and perhaps more ways to improve QoL and functioning will need to be researched and applied in clinical settings.
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Strengths and limitations
Our study suffers from a number of limitations, related both to our own analysis and to the STAR*D study design. It is important to note the original STAR*D study was not designed to accommodate comparison of level 2 interventions. It could be speculated that the lack of equipoise in patient randomization affected statistical power and, down the line, clinical significance. It would be useful to design another experiment specifically for this purpose, with a more balanced distribution of patients. Additionally, it would be informative to compare cognitive therapy to other forms of psychotherapy that have already proven their usefulness in treating MDD, such as interpersonal psychotherapy. 49 STAR*D lacked a control or a placebo group, which could have provided useful comparative data and helped control for the placebo effect and the passage of time as factors of remission. However, this may be of less significance for level 2 than for level 1 data. No blinding was required for the physicians and the patients involved. There is also a dearth of information regarding dropouts. Warden et al 50 have demonstrated that African-Americans, young patients, individuals with lower education, and patients with lower income were more likely to drop out of the STAR*D study than other groups. 50 The vast majority (90%) of cases of attrition in level 2 of the STAR*D study were shown to be motivated by nonmedical reasons. 51 This finding might explain why no difference was found in the percentage of patients that exited the study in the drug group compared with the cognitive therapy group, which lacked a drug side effect. 36 Medical predictors of attrition included medication side effects and the presence of Diagnostic and Statistical Manual of Mental Disorders (DSM) axis I comorbidities. 50 Attrition makes it more difficult to extrapolate conclusions from the sample studied to the general population; it is therefore important for future studies to account for missing data from attrition to avoid selection bias. Another potential weakness in this present analysis is the lack of control for coexisting symptoms, such as anxiety, insomnia, and loss of energy. Gaynes et al 52 have suggested that, while the latter do affect remission rates, symptoms such as loss of energy may guide medication selection according to side-effect profile. 52 One of the most important strengths of this present study is its examination of effect sizes. While STAR*D studies have traditionally analyzed results using P values, the current analysis uses Cohen's d in order to compare the relative strengths of the seven interventions. This estimation of magnitude serves to complement the statistical inference supplied by P values.
Another important strength was the reliance on PROs. The instruments have already demonstrated strong psychometric properties, and provided unique perspective on functional outcomes that are difficult to obtain by clinician rating. PROs were identified to play an important role not only in examining the impact of treatment interventions, but also in predicting relapse in MDD. 53 
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